文献速递膀胱癌与上尿路尿路上皮癌

评估肌层浸润性膀胱癌新辅助化疗完全缓解者的淋巴结侵犯风险

Assessing risk of lymph node invasion in complete responders to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
PubMed 文献 · BJU Int · 2024-06-24

本研究纳入2012至2022年在本中心接受新辅助化疗及根治性膀胱切除加盆腔淋巴结清扫的膀胱癌患者157例,完全病理缓解率为40.1%,淋巴结侵犯率为19%。完全缓解者淋巴结侵犯率显著低于未完全缓解者(3.2% vs 29.8%),且总生存、无转移生存和无病生存均更优。作者据此推测完全缓解者或可省略盆腔淋巴结清扫,但需前瞻性II期试验验证。

要点

  • 完全病理缓解率为40.1%,总体淋巴结侵犯率为19%。
  • 完全缓解者淋巴结侵犯率3.2%,显著低于未完全缓解者的29.8%。
  • 完全缓解者5年总生存、无转移生存和无病生存均优于未完全缓解者。

核心结论

  • 作者推测新辅助化疗后达到完全病理缓解的患者淋巴结侵犯风险极低,或可省略盆腔淋巴结清扫,但需前瞻性II期试验探索这一挑战性假设。

研究设计与样本

  • 单中心纳入2012至2022年接受新辅助化疗及根治性膀胱切除加盆腔淋巴结清扫的膀胱癌患者(cT2-4a、cN0、cM0),共157例。

主要发现

  • 总体完全病理缓解率为40.1%,淋巴结侵犯率为19%,淋巴结切除数中位数(四分位距)为26(19-36)。
  • 完全缓解者淋巴结侵犯率2例(3.2%)vs 未完全缓解者61例(29.8%),P < 0.001。
  • 调整淋巴结切除数后,完全缓解使淋巴结侵犯风险降低93%(比值比0.07,95%CI 0.01-0.25;P < 0.001)。
  • 完全缓解者 vs 未完全缓解者的5年总生存为69.7% vs 52.2%,无转移生存为68.3% vs 45.5%,无病生存为66.6% vs 43.5%。
  • 多因素调整后,完全缓解独立降低死亡风险(风险比0.44,95%CI 0.24-0.81;P = 0.008)、转移进展风险(风险比0.41,95%CI 0.23-0.71;P = 0.002)和疾病进展风险(风险比0.41,95%CI 0.24-0.70;P = 0.001)。

临床怎么用

  • 作者推测,新辅助化疗后达到完全病理缓解的患者或可省略盆腔淋巴结清扫,但需前瞻性II期试验探索。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the lymph node invasion (LNI) rate in patients exhibiting complete pathological response (CR) to neoadjuvant chemotherapy (NAC) and to test the association of CR status with lower LNI and better survival outcomes. MATERIALS AND METHODS: We included patients with bladder cancer (BCa; cT2-4a; cN0; cM0) treated with NAC and radical cystectomy (RC) + pelvic lymph node dissection (PLND) at our institution between 2012 and 2022 (N = 157). CR (ypT0) and LNI (ypN+) were defined at final pathology. Univariable and multivariable logistic regression analysis was performed to test the association between CR and LNI after adjusting for number of lymph nodes removed (NLR). Kaplan-Meier and Cox regression analyses were used to assess overall survival (OS), metastasis-free survival (MFS) and disease free-survival (DFS) according to CR status. RESULTS: Overall CR and LNI rates were 40.1% and 19%, respectively. The median (interquartile range [IQR]) NLR was 26 (19-36). The LNI rate was lower in patients with CR vs those without CR (2 [3.2%] vs 61 [29.8%]; P < 0.001). After adjusting for NLR, CR reduced the LNI risk by 93% (odds ratio 0.07, 95% confidence interval [CI] 0.01-0.25; P < 0.001). Kaplan-Meier plots depicted better 5-year OS (69.7 vs 52.2%), MFS (68.3 vs 45.5%) and DFS (66.6 vs 43.5%) in patients with CR vs those without CR. After multivariable adjustments, CR independently reduced the risk of death (hazard ratio [HR] 0.44, 95% CI 0.24-0.81; P = 0.008), metastatic progression (HR 0.41, 95% CI 0.23-0.71; P = 0.002) and disease progression (HR 0.41, 95% CI 0.24-0.70; P = 0.001). CONCLUSION: Based on these findings, we postulate that PLND could potentially be omitted in patients exhibiting CR after NAC, due to negligible risk of LNI. Prospective Phase II trials are needed to explore this challenging hypothesis.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Flammia RS, Tuderti G, Bologna E, et al. Assessing risk of lymph node invasion in complete responders to neoadjuvant chemotherapy for muscle-invasive bladder cancer. BJU Int. 2024. PMID: 38923233. doi:10.1111/bju.16440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。